IL2 and Disseminated intravascular coagulation: Interestingly, BrHPP and IL-2, followed by either no additional treatment or Vδ2-enriched autologous PBMC adoptive cell therapy with low-dose IL-2 as an adjunct only caused adverse effects, such as disseminated intravascular coagulation or tachyphylaxis with repeated dosing [12, 190, 191].